Low-level serum miR-24-2 is associated with the progression of colorectal cancer

He, Haowei; Wang, N.N.; Yi, Xiaoming; Tang, Chao; Wang, D.

doi:10.3233/cbm-170321

Cited by 16 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1d). As shown in Table 1, LINC00963 expression was related to TNM stage (P = 0.001), which diagnosis according to International Union Against Cancer (UICC) tumor TNM classification system [29], tumor differentiation status (P = 0.047), and lymph node metastasis (P = 0.007). The expression of LINC00963 in CRC cell lines was found to be significantly up-regulated in comparison with CCD-18Co (P < 0.001, Fig.…”

Section: Linc00963 Expression Was Significantly Up-regulated In Crc Cell Lines and Tissues And Was Related To The Poor Prognosis And Clinmentioning

confidence: 99%

LINC00963 affects the development of colorectal cancer via MiR-532-3p/HMGA2 axis

Liu

Tang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background LINC00963 is high-expressed in various carcinomas, but its expression and function in colorectal cancer (CRC) have not been explored. This study explored the role and mechanism of LINC00963 in CRC. Methods The expression of LINC00963 in CRC and its relationship with prognosis were examined by starBase and survival analysis. The effects of LINC00963, miR-532-3p and HMGA2 on the biological characteristics and EMT-related genes of CRC cells were studied by RT-qPCR, CCK-8, clone formation experiments, flow cytometry, scratch test, Transwell, and Western blot. Xenograft assay and immunohistochemistry were performed to verify the effect of LINC00963 on tumor growth. The correlation among LINC00963, miR-532-3p, and HMGA2 was analyzed by bioinformatics analysis, luciferase assay, and Pearson test. Results LINC00963 was high-expressed in CRC, and this was associated with poor prognosis of CRC. Silencing LINC00963 inhibited the activity, proliferation, migration, and invasion of CRC cells, MMP-3 and MMP-9 expressions, moreover, it also blocked cell cycle progression, and inhibited tumor growth and Ki67 expression. However, overexpression of LINC00963 showed the opposite effects to silencing LINC00963. LINC00963 targeted miR-532-3p to regulate HMGA2 expression. Down-regulation of miR-532-3p promoted cell proliferation, migration and invasion, and expressions of MMP-3 and MMP-9, and knockdown of HMGA2 reversed the effect of miR-532-3p inhibitor. Up-regulation of miR-532-3p inhibited the biological functions of CRC cells, and overexpression of HMGA2 reversed the miR-532-3p mimic effect. Conclusion LINC00963 affects the development of CRC through the miR-532-3p/HMGA2 axis.

show abstract

Section: Linc00963 Expression Was Significantly Up-regulated In Crc Cell Lines and Tissues And Was Related To The Poor Prognosis And Clinmentioning

confidence: 99%

LINC00963 affects the development of colorectal cancer via MiR-532-3p/HMGA2 axis

Liu

Tang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Until now, studies have reported that miR‐24‐2 is involved in the development of several tumours; for examples, miRNA‐24‐2 accelerates the development of tumours such as gastric cancer and breast cancer by enhancing the expression of oncogene c‐Myc . And miR‐24‐2 has gradually become an important marker for predicting cancer prognosis and tumour progression . Furthermore, miR‐24‐2 may act as an oncogene in clusters and promotes the metastasis of breast cancer .…”

Section: Discussionmentioning

confidence: 99%

“…Another research suggests the protein arginine methyltransferase 7 (PRMT7) repressed by miR‐24‐2 controls pluripotent factors Oct4, Nanog, Klf4 and c‐Myc . Furthermore, miR24‐2 may act as tumour biomarker . Strikingly, the amplification of miR24‐2 was confirmed in gastric cancer (GC) .…”

Section: Introductionmentioning

confidence: 99%

miR24‐2 accelerates progression of liver cancer cells by activating Pim1 through tri‐methylation of Histone H3 on the ninth lysine

Yang

Song

Meng

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Several microRNAs are associated with carcinogenesis and tumour progression. Herein, our observations suggest both miR24‐2 and Pim1 are up‐regulated in human liver cancers, and miR24‐2 accelerates growth of liver cancer cells in vitro and in vivo. Mechanistically, miR24‐2 increases the expression of N6‐adenosine‐methyltransferase METTL3 and thereafter promotes the expression of miR6079 via RNA methylation modification. Furthermore, miR6079 targets JMJD2A and then increased the tri‐methylation of histone H3 on the ninth lysine (H3K9me3). Therefore, miR24‐2 inhibits JMJD2A by increasing miR6079 and then increases H3K9me3. Strikingly, miR24‐2 increases the expression of Pim1 dependent on H3K9me3 and METTL3. Notably, our findings suggest that miR24‐2 alters several related genes (pHistone H3, SUZ12, SUV39H1, Nanog, MEKK4, pTyr) and accelerates progression of liver cancer cells through Pim1 activation. In particular, Pim1 is required for the oncogenic action of miR24‐2 in liver cancer. This study elucidates a novel mechanism for miR24‐2 in liver cancer and suggests that miR24‐2 may be used as novel therapeutic targets of liver cancer.

show abstract

“…miRNAs can be observed in the circulation alone or combined with some proteins; also, they can be released directly into extracellular fluids and carried by microvesicles, mostly exosomes [ 70 , 71 ]. miR-129 is highly expressed in CRC plasma, while miR-24-2 levels are low in CRC serum, thus representing potential positive or negative biomarkers in the diagnosis of CRC patients [ 41 , 42 ]. A study showed that serum expression levels of five miRNAs (miR-31, miR-141, miR-224-3p, miR-576-5p and miR-4669) were significantly different between patients with colon cancer and healthy controls, suggesting their potential use as a miRNA panel for diagnosis of CRC [ 43 ].…”

Section: Clinical Utility Of Liquid Biopsies In Patients With Colomentioning

confidence: 99%

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

et al. 2020

View full text Add to dashboard Cite

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high specificity and sensitivity in patients with colorectal cancer. A “liquid biopsy” is characterized by the isolation of cancer-derived components, such as circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs, and proteins, from peripheral blood or other body fluids and their genomic or proteomic assessment. The liquid biopsy is a minimally invasive and repeatable technique that could play a significant role in screening and diagnosis, and predict relapse and metastasis, as well as monitoring minimal residual disease and chemotherapy resistance in colorectal cancer patients. However, there are still some practical issues that need to be addressed before liquid biopsy can be widely used in clinical practice. Potential challenges may include low amounts of circulating tumor cells and circulating tumor DNA in samples, lack of pre-analytical and analytical consensus, clinical validation, and regulatory endorsement. The aim of this review was to summarize the current knowledge of the role of liquid biopsy in the management of colorectal cancer.

show abstract

Low-level serum miR-24-2 is associated with the progression of colorectal cancer

Abstract: Serum miR-24-2 is a potential negative biomarker in the diagnosis of the progression of CRC patients and associated with biochemical indices.

Cited by 16 publications

References 23 publications

LINC00963 affects the development of colorectal cancer via MiR-532-3p/HMGA2 axis

LINC00963 affects the development of colorectal cancer via MiR-532-3p/HMGA2 axis

miR24‐2 accelerates progression of liver cancer cells by activating Pim1 through tri‐methylation of Histone H3 on the ninth lysine

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

Contact Info

Product

Resources

About